☆ 4.7 Letter

Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod

CNS NEUROSCIENCE & THERAPEUTICS (2018)

Get Full Text
Add to Collection

Journal

CNS NEUROSCIENCE & THERAPEUTICS
Volume 24, Issue 10, Pages 984-986

Publisher

WILEY
DOI: 10.1111/cns.12992

Keywords

Disease activity; Disease reactivation; FTY; Gilenya; MS relapse

Categories

Neurosciences Pharmacology & Pharmacy

Funding

  1. Biogen
  2. Novartis
  3. Teva
  4. Genzyme
  5. Merk
  6. Genzyme Sanofi
  7. Merck
  8. Swiss National Science Foundation [310030_175561/1]
  9. Swiss National Fonds (SNF) [310030_172952]
  10. UCB
  11. Biogen Idec
  12. Swiss National Science Foundation (SNF) [310030_175561, 310030_172952] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.